Cuvitru (human normal immunoglobulin): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Cuvitru 200 mg/ml solution for subcutaneous injection

Indications for subcutaneous administration (SCIg)

Replacement therapy in adults, and children and adolescents (0-18 years) in:

• Primary immunodeficiency syndromes with impaired antibody production.

• Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated.

• Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.

• Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).


Route of administration: Injectable
Molecule: human normal immunoglobulin

Patients' opinions on Cuvitru

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.